Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Tomohiro Sugawara
Multicenter Phase II Clinical Trial of Nilotinib for Patients With Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia From the East Japan CML Study Group Evaluation of Molecular Response and the Efficacy and Safety of Nilotinib
Biomarker Research
Biochemistry
Molecular Medicine
Clinical Biochemistry
Related publications
Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Long-Term Safety and Efficacy of Dasatinib in the Treatment of Chronic-Phase Chronic Myeloid Leukemia Patients Resistant or Intolerant to Imatinib
Blood and Lymphatic Cancer: Targets and Therapy
Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients With Chronic Myeloid Leukemia
Biological and Pharmaceutical Bulletin
Medicine
Pharmacology
Pharmaceutical Science
Long-Term Efficacy and Safety of Dasatinib in Patients With Chronic Myeloid Leukemia in Accelerated Phase Who Are Resistant to or Intolerant of Imatinib
Blood Cancer Journal
Oncology
Hematology
Pancreatic Enzyme Elevation in Chronic Myeloid Leukemia Patients Treated With Nilotinib After Imatinib Failure
Haematologica
Hematology
Long-Term Molecular and Cytogenetic Response and Survival Outcomes With Imatinib 400 Mg, Imatinib 800 Mg, Dasatinib, and Nilotinib in Patients With Chronic-Phase Chronic Myeloid Leukaemia: Retrospective Analysis of Patient Data From Five Clinical Trials
The Lancet Haematology
Hematology
Budget Impact Analysis or Pharmacological Therapy of Chronic Myeloid Leukemia (Cml) With Nilotinib as the Second-Line Treatment in Russian Federation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Satisfaction With Information on Nilotinib Treatment in Chronic Myeloid Leukemia Patients
Acta Oncologica
Nuclear Medicine
Radiology
Hematology
Oncology
Medicine
Imaging
Complete Molecular Response Induced by Nilotinib in a Patient Previously Treated With Imatinib, Nilotinib and Dasatinib
Clinical Management Issues
Medicine
Accounting
Management
Business
